Related Experiment Video

Updated: Nov 1, 2025

Detection and Visualization of DNA Damage-induced Protein Complexes in Suspension Cell Cultures Using the Proximity Ligation Assay
13:10

Detection and Visualization of DNA Damage-induced Protein Complexes in Suspension Cell Cultures Using the Proximity Ligation Assay

Published on: June 9, 2017

10.2K

Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma

Yi Zhao1, Juan Yang1, Jiarui Liu1

  • 1Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250021, China.

Cell Death & Disease
|June 24, 2021
PubMed

Insights

Polo-like kinase 4 (PLK4) inhibition shows promise for treating diffuse large B-cell lymphoma (DLBCL). PLK4 inhibitor CFI-400945, alone or with doxorubicin, reduced DLBCL tumor growth and improved patient survival.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Medicine

Background:

  • Polo-like kinase 4 (PLK4) is crucial for centriole biogenesis and implicated in tumorigenesis.
  • The role of PLK4 in diffuse large B-cell lymphoma (DLBCL) remains unclear.
  • Targeting PLK4 may enhance chemotherapy efficacy.

Purpose of the Study:

  • To investigate PLK4 as a therapeutic target in DLBCL.
  • To evaluate the efficacy of the PLK4 inhibitor CFI-400945 in DLBCL models.
  • To explore the mechanisms underlying CFI-400945's anti-tumor effects.

Main Methods:

  • In vitro studies using DLBCL cell lines treated with CFI-400945.
  • Assessment of cell proliferation, apoptosis, and mitotic defects.
  • Analysis of p53 and Hippo/YAP signaling pathways.
  • In vivo studies using DLBCL xenograft models.
  • Analysis of PLK4 expression in patient samples.

Main Results:

  • CFI-400945 inhibited DLBCL cell proliferation and induced apoptosis, causing mitotic defects.
  • PLK4 inhibition activated p53 and Hippo/YAP tumor suppressor pathways and DNA damage response.
  • Combination therapy with doxorubicin significantly delayed tumor progression in vivo.
  • Elevated PLK4 levels in DLBCL tissues correlated with poor survival in patients treated with CHOP-based regimens.

Conclusions:

  • PLK4 is a viable therapeutic target for DLBCL treatment.
  • CFI-400945 demonstrates efficacy as a monotherapy and in combination with doxorubicin.
  • PLK4 expression may serve as a predictive biomarker for DLBCL chemosensitivity.

More Related Videos

Enhancing Tumor Content through Tumor Macrodissection10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.2K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

17.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.6K
DNA Damage Can Stall the Cell Cycle02:37

DNA Damage Can Stall the Cell Cycle

2.8K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.2K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.3K